Almirall, S.a.

Almirall Prodesfarma S.a.

Laboratorios Almirall, S.a.

Lluis Miquel Pages Santacana

Paul Robert Eastwood

Silvia Fonquerna Pou

Carles Puig Duran

Jordi Bach Taña

Alex Haahr Gouliaev

Thomas Franch

Maria Antonia Buil Albero

Joan Taltavull Moll

Maria Dolors Fernandez Forner

Jordi Gracia Ferrer

Luigi Piero Stasi

Juan Francisco Caturla Javaloyes

Montserrat Erra Sola

Victor Giulio Matassa

Vittorio Dal Piaz

Marta Carrascal Riera

Lidia Soca Pueyo

Francisco Javier Bernal Anchuela

Yolanda Garrido Rubio

Jacob Gonzalez Rodrigues

Antonia Maria Buil Albero

Maria Begoña Hernandez Olasagarre

Gaspar Casals Coll

Marta Mir Cepeda

Ian Sarvary

Soren Jensby Nielsen

New pyrrolotriazinone derivatives having the chemical structure of Formula (I) are disclosed; as well as process for theft preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks). 

Pyrrolotriazinone derivatives as PI3K inhibitors

New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK). 

Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors

New pyridin-2(1H)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK). 

Pyridin-2(1 H)-one derivatives as JAK inhibitors

The invention relates to new therapeutically useful pyridazin-3(2H)-one derivatives of Formula (I) and to pharmaceutical compositions containing them. These compounds are potent and selective inhibitors of phosphodiesterase 4 (PDE4) and are thus useful in the treatment, prevention or suppression of pathological conditions, diseases and disorders known to be susceptible of being improved by inhibition of PDE4 such as asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis or irritable bowel disease. 

[object Object]

The invention relates to indolyl piperidinyl derivatives of formula (I) wherein: Arepresents an alkylene, alkyleneoxy, alkylenethio, alkanoylene or hydroxyalkylene group; Arepresents an alkylene, alkyleneoxy, alkylenethio, alkanoylene or an alkyleneoxyalkylene group; Wrepresents a phenylene, furanylene or pyridinylene group which is unsubstituted or substituted by one or more halogen atoms, alkoxy groups and/or alkyl groups; Wrepresents a 3&#x2013;10 membered monocyclic or bicyclic group containing from 1 to 3 heteroatoms said group being unsubstituted or substituted by one or more halogen atoms, alkyl groups, alkoxy groups and/or oxo groups; Rrepresents a hydrogen or halogen atom or an alkyl, alkoxy or methylamino group; and Rrepresents a carboxyl group; and pharmaceutically acceptable salts thereof; to processes for their preparation; to pharmaceutical compositions containing them; and to their medical use as antihistaminic and antiallergic agents.

Indolylpiperidine derivatives as antihistaminic and antiallergic agents

Growing community of inventors

Barcelona, Spain

Lluis Miquel Pages Santacana